Impact of New Vaccine Introduction on Developing Country Immunization Programs and Health Systems
M. Favin,Ryan Macabasco,R. Steinglass
Abstract:s, and WHO regional office databases. In addition, internet searches of agencies working on immunization and vaccine introduction were searched. From the hundreds of documents examined, the USAID/MCHIP team selected 61 that contained information on the impact of new vaccine introduction (NUVI) on immunization programs and, in a few cases, the broader health system. Most of the documents were Post-Introduction Evaluations (PIEs), PIE summaries, meeting reports and presentations, and consultant reports. Most dealt with one NUVI but a few covered multiple country experiences (one summarized 16 PIEs, another seven). Country experiences reviewed were mostly from low-income African countries and concerned introductions of HepB and Hib, although there were several cases from middle-income countries, other continents, and rotavirus, pneumococcal vaccines, and human papillovirus vaccines (RV, PCV, and HPV). To summarize relevant information, MCHIP used a format based on the WHO health systems components, with separate columns for impact on the EPI and health system. Limitations: ►Most documents about EPI, but not about NUVI specifically, failed to mention the effects of NUVI on the EPI or health system; most documents on NUVI focused on the preparation and introduction, or the EPI status shortly after the introduction. ►PIEs and other NUVI assessments report on a particular point in time, which may fail to capture the changing effects of NUVI over time. ►In many cases only PIE summaries from WHO were available rather than full documents, and they sometimes contained contradictory or incomplete information. ►It was difficult to separate the effects of NUVI from the effects of donor funding that often accompanied NUVI. ►Because introductions of PCV, RV, and HPV into developing countries began only a few years ago, there was limited information on their impact, so the review may not